Press releases

  08/07/2021 08:00
|

Quantum Genomics Enrolls First Patient in Its Pivotal Phase III REFRESH Trial of Firibastat in Difficult-to-treat and Resistant Hypertension with Once-a-day Formulation of Firibastat.

  05/07/2021 08:00
|

Presentation of the Effects of QGC606 in an Experimental Model of Heart Failure at the Annual Congress of the European Society of Cardiology

  28/06/2021 18:00
|

QUORUM study : Results Announcement next August 27, 2021 at 10:30 am CEST

  19/05/2021 18:10
|

Quantum Genomics Announces the Publication of New Scientific Article in Biomedecine et Pharmacotherapy which further strengthen its Phase III development plan in difficult to treat and resistant hypertension

  28/04/2021 18:00
|

Quantum Genomics Secures 3 Million euros Non-dilutive Financing

  21/04/2021 08:00
|

Quantum Genomics will Present Top-line Results from its QUORUM study of Firibastat in Heart Failure post Myocardial Infarction at the European Society of Cardiology (ESC) Meeting

  20/04/2021 08:00
|

Quantum Genomics announces the end of its collaboration with Chinese Pharma Qilu in the development and commercialization of firibastat in China

  25/03/2021 18:00
|

Quantum Genomics Reports Full Year 2020 Operating and Financial Results

  09/02/2021 18:00
|

Orient EuroPharma Acquires Equity Stake in Quantum Genomics

  18/01/2021 08:00
|

Quantum Genomics Launches Phase III Pivotal REFRESH Study in Difficult-to-treat/Resistant Hypertension with Once-a-day Formulation of Firibastat